How many clinical trials are studying daraxonrasib?

7 recruiting trials in our tracked data involve daraxonrasib.

What conditions is daraxonrasib being studied for?

In our tracked recruiting trials, daraxonrasib is being studied in trials for Lung cancer, Pancreatic Cancer, Colorectal Cancer.

daraxonrasib: clinical trials recruiting now

Q: Is daraxonrasib FDA-approved?

Yes. According to the FDA drug label available through openFDA, daraxonrasib is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. daraxonrasib appears in the FDA drug-label database. Marketed as RASONQUE.

FDA-approved use

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. RASONQUE is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. ( 1 )

FDA label via openFDA

Phase breakdown

Phase 1 3 Phase 2 3 Phase 3 3

Conditions being studied

Condition	Trials
Lung cancer · daraxonrasib for Lung cancer	5
Pancreatic Cancer · daraxonrasib for Pancreatic Cancer	5
Colorectal Cancer · daraxonrasib for Colorectal Cancer	3
NSCLC · daraxonrasib for NSCLC	3
Non-Small Cell Lung Cancer (NSCLC) · daraxonrasib for Non-Small Cell Lung Cancer (NSCLC)	3
PDAC · daraxonrasib for PDAC	3
Advanced Solid Tumors	2
CRC	2
Colorectal Cancer (CRC)	2
PDAC - Pancreatic Ductal Adenocarcinoma	2
Pancreatic Adenocarcinoma	2
Pancreatic Ductal Adenocarcinoma (PDAC)	2
Lung Cancer (NSCLC)	1
Melanoma	1
Metastatic Solid Tumors	1

Recruiting trials involving daraxonrasib

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 57 locations
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 153 locations
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations

Common questions

Is daraxonrasib FDA-approved?

Yes, marketed as RASONQUE.

How many recruiting trials involve daraxonrasib?

7 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.